Home › Companies › Ionis Pharmaceuticals, Inc. › 2025-2026

Ionis Pharmaceuticals, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Ionis Pharmaceuticals, Inc.’s Form 8-K, filed June 8, 2026 (Item 5.07 on EDGAR). Page generated October 14, 2026.

6Ballot items
480Asset managers
3,307Fund votes
June 4, 2026Meeting date

Results at a glance

Meeting of June 4, 2026: 6 items on Ionis Pharmaceuticals, Inc.’s Form 8-K, filed June 8, 2026: 4 approved · 2 without a stated outcome.

Material dissent

3. Approval of an amendment of the Amended and Restated Ionis Pharmaceuticals, Inc 77% of votes cast Approved Under 80%

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Ionis Pharmaceuticals, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Ionis Pharmaceuticals, Inc.

These tallies are Ionis Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 8, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Ionis Pharmaceuticals, Inc. — official shareholder meeting results, meeting held June 4, 2026
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Support (of votes cast)	Reported outcome	Voting standard
Elect Director: Spencer R. Berthelsen	119,824,353	20,816,547	98,115	--	12,305,695	85%	Not verified	—
Elect Director: Joan E. Herman	135,599,646	5,076,895	62,474	--	12,305,695	96%	Not verified	—
2. An advisory vote on the compensation paid to the Company's executive officers, including the following resolution: "RESOLVED, that Ionis' stockholders approve, on an advisory (nonbinding) basis, the compensation of the named executive officers, as disclosed	135,537,973	5,088,105	112,937	--	12,305,695	96%	Approved	—
3. Approval of an amendment of the Amended and Restated Ionis Pharmaceuticals, Inc	108,377,084	32,303,288	58,643	--	12,305,695	77%	Approved	—
4. Approve an amendment of the Amended and Restated 2000 Employee Stock Purchase Plan to increase the number of shares of common stock authorized for issuance under such plan by 750,000 shares and to remove the termination date of the plan	140,348,001	332,204	58,810	--	12,305,695	99.7%	Approved	—
5. Ratify the Audit Committee's selection of Ernst & Young LLP as independent auditors for the 2026 fiscal year	148,893,646	4,000,539	150,525	--	0	97%	Approved	—

Source: Ionis Pharmaceuticals, Inc., Form 8-K, filed with the SEC on June 8, 2026 — read the filing on EDGAR.

How asset managers voted at the Ionis Pharmaceuticals, Inc. 2025-2026 meeting

Each item below shows how the 480 asset managers that disclosed a Ionis Pharmaceuticals, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. Elect Director: Joan E. Herman

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 5 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%

FOR: 135,599,646AGAINST: 5,076,895

Details: description as filed, official tally, votes by 116 asset managers

Description as filed by funds: Election of Directors: Joan E. Herman

Ionis Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Joan E. Herman”): 135,599,646 for, 5,076,895 against, per its Form 8-K filed June 8, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 116 asset managers below reported 81,012,934 for, 2,283,538 against, 1,764 abstained, 160 not voted.

FOR

FOR: 81,012,934AGAINST: 2,283,538ABSTAIN: 1,764NOT VOTED: 160

Largest asset managers voting on “Election of Directors: Joan E. Herman” at Ionis Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Against	Vote
Vanguard	19,414,463	14	For
Fidelity	17,072,170	0	For
Capital Group	15,689,002	0	For
T. Rowe Price	3,173,586	2,132,721	Mixed
NEW ECONOMY FUND	4,723,802	0	For
BlackRock	3,679,155	0	For
TWEEDY, BROWNE FUND INC.	1,963,162	0	For
Charles Schwab	1,536,094	0	For
State Street	1,308,413	0	For
JPMorgan	1,296,917	0	For
American Century	1,275,849	0	For
Jackson National	982,760	0	For
Franklin Custodian Funds	800,000	0	For
Waddell & Reed	598,636	0	For
MUTUAL FUND SERIES TRUST	594,587	0	For
MFS	573,889	0	For
Invesco	546,518	0	For
TIAA	459,061	0	For
First Trust	411,205	0	For
Neuberger Berman	350,745	0	For
FRANKLIN STRATEGIC SERIES	347,272	0	For
Goldman Sachs	341,791	0	For
Bridge Builder Trust	333,637	0	For
ARK ETF Trust	269,786	0	For
MassMutual	258,430	0	For

Showing the 25 largest of 116 asset managers. See all 116 in the interactive database.

2. Elect Director: Spencer R. Berthelsen

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 5 wordings of this item as funds reported it.

85% Majority: yes · of votes cast

FOR 85%AGAINST

FOR: 119,824,353AGAINST: 20,816,547

Details: description as filed, official tally, votes by 116 asset managers

Description as filed by funds: Election of Directors: Spencer R. Berthelsen

Ionis Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Spencer R. Berthelsen”): 119,824,353 for, 20,816,547 against, per its Form 8-K filed June 8, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 85% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 116 asset managers below reported 74,662,443 for, 8,634,029 against, 1,764 abstained, 160 not voted.

FOR

FOR: 74,662,443AGAINST: 8,634,029ABSTAIN: 1,764NOT VOTED: 160

Largest asset managers voting on “Election of Directors: Spencer R. Berthelsen” at Ionis Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Against	Vote
Vanguard	19,403,967	10,510	For
Fidelity	17,072,170	0	For
Capital Group	15,689,002	0	For
T. Rowe Price	0	5,306,307	Against
NEW ECONOMY FUND	4,723,802	0	For
BlackRock	3,679,155	0	For
TWEEDY, BROWNE FUND INC.	1,963,162	0	For
Charles Schwab	1,536,094	0	For
State Street	4,038	1,304,375	Against
JPMorgan	1,296,917	0	For
American Century	1,275,849	0	For
Jackson National	490,004	492,756	Mixed
Franklin Custodian Funds	800,000	0	For
Waddell & Reed	0	598,636	Against
MUTUAL FUND SERIES TRUST	594,587	0	For
MFS	573,889	0	For
Invesco	546,518	0	For
TIAA	459,061	0	For
First Trust	411,205	0	For
Neuberger Berman	350,745	0	For
FRANKLIN STRATEGIC SERIES	347,272	0	For
Goldman Sachs	341,791	0	For
Bridge Builder Trust	333,637	0	For
ARK ETF Trust	269,786	0	For
MassMutual	8,419	250,011	Against

Showing the 25 largest of 116 asset managers. See all 116 in the interactive database.

3. 4. Approve an amendment of the Amended and Restated 2000 Employee Stock Purchase Plan to increase the number of shares…

Official resultCOMPENSATIONReported outcome: Approved

Combines 4 wordings of this item as funds reported it.

99.7% Approved · of votes cast

FOR 99.7%

FOR: 140,348,001AGAINST: 332,204

Details: description as filed, official tally, votes by 122 asset managers

Description as filed by funds: To approve an amendment of the Amended and Restated 2000 Employee Stock Purchase Plan to increase the number of shares of common stock authorized for purchase under such plan by 750,000 shares and remove the termination date of the plan.

Ionis Pharmaceuticals, Inc.’s own tally for this item (“4. Approve an amendment of the Amended and Restated 2000 Employee Stock Purchase Plan to increase the number of shares of common stock authorized for issuance under such plan by 750,000 shares and to remove the terminati”): 140,348,001 for, 332,204 against — passed, per its Form 8-K filed June 8, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved the foregoing proposal.”
Support: 99.7% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of Ionis Pharmaceuticals, Inc.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Amend Omnibus Stock Plan” (5 managers, Fund and manager reports combined; may count the same shares twice; no share total shown).

The 122 asset managers below reported 83,838,470 for, 1,765 against, 160 not voted.

FOR

FOR: 83,838,470AGAINST: 1,765NOT VOTED: 160

Largest asset managers voting on “To approve an amendment of the Amended and Restated 2000 Employee Stock Purchase Plan to increase the number o” at Ionis Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Against	Vote
Vanguard	19,414,476	1	For
Fidelity	17,072,170	0	For
Capital Group	15,689,002	0	For
T. Rowe Price	5,306,307	0	For
NEW ECONOMY FUND	4,723,802	0	For
BlackRock	3,679,155	0	For
TWEEDY, BROWNE FUND INC.	1,963,162	0	For
Charles Schwab	1,536,094	0	For
State Street	1,308,413	0	For
JPMorgan	1,296,917	0	For
American Century	1,275,849	0	For
Jackson National	982,760	0	For
Franklin Custodian Funds	800,000	0	For
Waddell & Reed	598,636	0	For
MUTUAL FUND SERIES TRUST	594,587	0	For
MFS	573,889	0	For
Invesco	546,518	0	For
Eversept Partners, LP	498,800	0	For
TIAA	459,061	0	For
First Trust	411,205	0	For
Neuberger Berman	350,745	0	For
FRANKLIN STRATEGIC SERIES	347,272	0	For
Goldman Sachs	341,791	0	For
Bridge Builder Trust	333,637	0	For
ARK ETF Trust	269,786	0	For

Showing the 25 largest of 122 asset managers. See all 122 in the interactive database.

4. 3. Approval of an amendment of the Amended and Restated Ionis Pharmaceuticals, Inc

Official resultCOMPENSATIONReported outcome: Approved

Combines 2 wordings of this item as funds reported it.

77% Approved · of votes cast

FOR 77%AGAINST

FOR: 108,377,084AGAINST: 32,303,288

Details: description as filed, official tally, votes by 117 asset managers

Description as filed by funds: To approve an amendment of the Amended and Restated Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance under such plan by 9,500,000 shares to an aggregate of 52,000,000 shares.

Ionis Pharmaceuticals, Inc.’s own tally for this item (“3. Approval of an amendment of the Amended and Restated Ionis Pharmaceuticals, Inc”): 108,377,084 for, 32,303,288 against — passed, per its Form 8-K filed June 8, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved the foregoing proposal.”
Support: 77% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 117 asset managers below reported 69,359,617 for, 13,792,761 against, 3,564 abstained, 160 not voted.

FORAGAINST

FOR: 69,359,617AGAINST: 13,792,761ABSTAIN: 3,564NOT VOTED: 160

Largest asset managers voting on “To approve an amendment of the Amended and Restated Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan to ” at Ionis Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Against	Vote
Vanguard	19,414,372	105	For
Fidelity	3,494,139	13,578,031	Mixed
Capital Group	15,689,002	0	For
T. Rowe Price	5,306,307	0	For
NEW ECONOMY FUND	4,723,802	0	For
BlackRock	3,679,155	0	For
TWEEDY, BROWNE FUND INC.	1,963,162	0	For
Charles Schwab	1,536,094	0	For
State Street	1,308,400	13	For
JPMorgan	1,296,917	0	For
American Century	1,275,849	0	For
Jackson National	982,760	0	For
Franklin Custodian Funds	800,000	0	For
Waddell & Reed	598,636	0	For
MUTUAL FUND SERIES TRUST	594,587	0	For
MFS	573,889	0	For
Invesco	546,518	0	For
TIAA	459,061	0	For
First Trust	411,205	0	For
Neuberger Berman	350,745	0	For
FRANKLIN STRATEGIC SERIES	347,272	0	For
Goldman Sachs	341,791	0	For
Bridge Builder Trust	333,637	0	For
ARK ETF Trust	269,786	0	For
MassMutual	258,430	0	For

Showing the 25 largest of 117 asset managers. See all 117 in the interactive database.

5. 2. An advisory vote on the compensation paid to the Company's executive officers, including the following resolution…

Official result Fund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 8 wordings of this item as funds reported it.

96% Approved · of votes cast

FOR 96%

FOR: 135,537,973AGAINST: 5,088,105

Details: description as filed, official tally, votes by 480 asset managers

Description as filed by funds: To make an advisory vote on executive compensation.

Ionis Pharmaceuticals, Inc.’s own tally for this item (“2. An advisory vote on the compensation paid to the Company's executive officers, including the following resolution: "RESOLVED, that Ionis' stockholders approve, on an advisory (nonbinding) basis, the compensation of th”): 135,537,973 for, 5,088,105 against — passed, per its Form 8-K filed June 8, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved the foregoing proposal.”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 114 asset managers voting on “To make an advisory vote on executive compensation.” at Ionis Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Against	Vote
Vanguard	19,414,466	11	For
Fidelity	17,072,170	0	For
Capital Group	15,689,002	0	For
T. Rowe Price	5,306,307	0	For
NEW ECONOMY FUND	4,723,802	0	For
BlackRock	3,679,155	0	For
TWEEDY, BROWNE FUND INC.	1,963,162	0	For
Charles Schwab	1,536,094	0	For
State Street	1,308,413	0	For
JPMorgan	1,296,917	0	For
American Century	1,275,849	0	For
Jackson National	831,772	150,988	Mixed
Franklin Custodian Funds	800,000	0	For
Waddell & Reed	598,636	0	For
MUTUAL FUND SERIES TRUST	594,587	0	For
MFS	573,889	0	For
Invesco	0	546,518	Against
TIAA	459,061	0	For
First Trust	411,205	0	For
Neuberger Berman	350,745	0	For
FRANKLIN STRATEGIC SERIES	347,272	0	For
Goldman Sachs	341,791	0	For
Bridge Builder Trust	333,637	0	For
ARK ETF Trust	269,786	0	For
MassMutual	258,430	0	For

Fund voting reports, all 114 managers: 82,443,679 for, 780,603 against, 1,764 abstained, 160 not voted, 216 mixed. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 395 asset managers voting on “To make an advisory vote on executive compensation.” at Ionis Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Against	Vote
Fidelity	24,401,303	165	For
Capital Group	21,161,984	0	For
T. Rowe Price	9,154,786	0	For
Wellington	5,622,981	0	For
BlackRock	4,399,050	0	For
GEODE CAPITAL MANAGEMENT, LLC	3,980,754	0	For
RBC Global Asset Management (U.S.) Inc.	2,322,181	0	For
Tweedy, Browne Co LLC	2,158,924	0	For
DEERFIELD MANAGEMENT COMPANY, L.P.	1,979,669	0	For
State Street	1,871,757	3,841	For
Deep Track Capital, LP	1,748,458	0	For
Artisan	1,693,539	0	For
Charles Schwab	1,585,478	0	For
FRANKLIN ADVISERS INC	1,567,672	0	For
Polar Capital Holdings Plc	1,565,932	0	For
American Century	1,363,046	0	For
PICTET ASSET MANAGEMENT SA	1,318,567	0	For
Vanguard	1,280,227	0	For
SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC	1,096,374	0	For
BNP Paribas Asset Management Holding S.A.	0	867,805	Against
Invesco	0	858,410	Against
UBS	0	846,683	Against
Northern Trust	793,126	0	For
GROUPAMA ASSET MANAGMENT	743,355	0	For
NOMURA INVESTMENT MANAGEMENT BUSINESS TRUST	730,020	0	For

Institutional-manager reports, all 395 managers: 106,047,718 for, 4,098,388 against, 7,444 abstained, 2,603 not voted. Showing the 25 largest; see all in the interactive database.

6. 5. Ratify the Audit Committee's selection of Ernst & Young LLP as independent auditors for the 2026 fiscal year

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 3 wordings of this item as funds reported it.

97% Approved · of votes cast

FOR 97%

FOR: 148,893,646AGAINST: 4,000,539

Details: description as filed, official tally, votes by 116 asset managers

Description as filed by funds: To ratify the Audit Committee's selection of Ernst & Young LLP as independent auditors for the 2026 fiscal year.

Ionis Pharmaceuticals, Inc.’s own tally for this item (“5. Ratify the Audit Committee's selection of Ernst & Young LLP as independent auditors for the 2026 fiscal year”): 148,893,646 for, 4,000,539 against — passed, per its Form 8-K filed June 8, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved the foregoing proposal.”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 116 asset managers below reported 83,278,408 for, 18,064 against, 1,764 abstained, 160 not voted.

FOR

FOR: 83,278,408AGAINST: 18,064ABSTAIN: 1,764NOT VOTED: 160

Largest asset managers voting on “To ratify the Audit Committee's selection of Ernst & Young LLP as independent auditors for the 2026 fiscal yea” at Ionis Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Against	Vote
Vanguard	19,404,026	10,451	For
Fidelity	17,072,170	0	For
Capital Group	15,689,002	0	For
T. Rowe Price	5,306,307	0	For
NEW ECONOMY FUND	4,723,802	0	For
BlackRock	3,679,155	0	For
TWEEDY, BROWNE FUND INC.	1,963,162	0	For
Charles Schwab	1,536,094	0	For
State Street	1,308,364	49	For
JPMorgan	1,296,917	0	For
American Century	1,275,849	0	For
Jackson National	982,760	0	For
Franklin Custodian Funds	800,000	0	For
Waddell & Reed	598,636	0	For
MUTUAL FUND SERIES TRUST	594,587	0	For
MFS	573,889	0	For
Invesco	546,518	0	For
TIAA	459,061	0	For
First Trust	411,205	0	For
Neuberger Berman	350,745	0	For
FRANKLIN STRATEGIC SERIES	347,272	0	For
Goldman Sachs	341,791	0	For
Bridge Builder Trust	333,637	0	For
ARK ETF Trust	269,786	0	For
MassMutual	258,430	0	For

Showing the 25 largest of 116 asset managers. See all 116 in the interactive database.

Largest Ionis Pharmaceuticals, Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 165,262,556 shares outstanding at the time of that meeting.

Fund voting reports: top Ionis Pharmaceuticals, Inc. shareholders by shares voted on “To make an advisory vote on executive compensation.”, 2025-2026
#	Asset manager	% of shares outstanding
1	Vanguard	11.75%
2	Fidelity	10.33%
3	Capital Group	9.49%
4	T. Rowe Price	3.21%
5	NEW ECONOMY FUND	2.86%
6	BlackRock	2.23%
7	TWEEDY, BROWNE FUND INC.	1.19%
8	Charles Schwab	0.93%
9	State Street	0.79%
10	JPMorgan	0.78%

Institutional-manager reports: top Ionis Pharmaceuticals, Inc. shareholders by shares voted on “To make an advisory vote on executive compensation.”, 2025-2026
#	Asset manager	% of shares outstanding
1	Fidelity	14.77%
2	Capital Group	12.81%
3	T. Rowe Price	5.54%
4	Wellington	3.40%
5	BlackRock	2.66%
6	GEODE CAPITAL MANAGEMENT, LLC	2.41%
7	RBC Global Asset Management (U.S.) Inc.	1.41%
8	Tweedy, Browne Co LLC	1.31%
9	DEERFIELD MANAGEMENT COMPANY, L.P.	1.20%
10	State Street	1.13%

Reported Ionis Pharmaceuticals, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

Ionis Pharmaceuticals, Inc. holdings and ownership disclosed for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
FMR (Fidelity)	14.86%	13F
FMR LLC	13.02%	DEF14A
Capital World Investors	12.82%	13G
Vanguard Group	9.95%	13F
BlackRock	6.32%	13F
Two Sigma	3.54%	13F
State Street	2.42%	13F
T. Rowe Price	1.83%	13F
JPMorgan Chase	1.43%	13F
Goldman Sachs	1.03%	13F

Percentages above are of 165,262,556 shares outstanding, as reported by Ionis Pharmaceuticals, Inc. on its Form 10-Q dated April 23, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Ionis Pharmaceuticals, Inc.’s 10-Q dated April 23, 2026. This page is a static snapshot rebuilt weekly on October 14, 2026; a live search always shows the current data.

At Ionis Pharmaceuticals, Inc.'s shareholder meeting held June 4, 2026, in the 2025-2026 proxy season, 480 asset managers reported how they voted on 6 ballot items in their SEC Form N-PX filings, covering 3,307 separate fund positions. On the most widely held item on that ballot — To make an advisory vote on executive compensation. — Ionis Pharmaceuticals, Inc.'s filing reports the proposal as approved, with 96% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Ionis Pharmaceuticals, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 8, 2026.

Ionis Pharmaceuticals, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Download data (CSV): ballot items · votes by manager · column guide.